



IFW

Attorney Docket No. P71167US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of Sheriff et al.

Application No.: 10/572,875

Filed: March 22, 2006

For: COMPOUNDS FOR NEUTRALIZING THE EFFECTS OF SECRETED PLA2 IIA

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure, references are cited on the attached Form PTO-1449 and, as appropriate, copies of the cited references are attached. Relevance of cited references is indicated in the attached search report on a corresponding foreign application.


The Menschikowski publication identified on the attached PTO-1449 was previously submitted with the Applicant's IDS filed on April 6, 2006. This publication is resubmitted herewith because the description of the Menschikowski publication on the PTO-1449 of April 6, 2006, was incomplete.

This paper is being filed before first action on the merits or within 3 months of the application filing date or date of entry into the national stage. Accordingly, no fee is required. Should a fee be required, please charge it to Deposit Account No. 06-1358.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By:

  
William E. Player  
Reg. No. 31,409

400 Seventh Street, N.W.  
Washington, DC 20004  
Tel. (202) 638-6666  
Fax (202) 393-5350  
Date: May 2, 2006  
WEP/jhr

R:\rthomas\wep\2006\May\P71167US0 IDS.wpd



Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Attorney Docket - P71167US0

Application No. - 10/572,875

Applicant - Sheriff et al.

Filing Date - March 22, 2006

## U.S. PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Document No.	Date	Patentee/Applicant

## FOREIGN PATENT DOCUMENTS

	Country	Document No.	Translation	Abstract	Date	Patentee
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		

## NON-PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)
		Hundley, T.R. et al., "Characteristics of Arachidonic Acid Generation in Human Basophils: Relationship Between the Effects of Inhibitors of Secretory Phospholipase A <sub>2</sub> Activity and Leukotriene C <sub>4</sub> Release," The Journal of Pharmacology and Experimental Therapeutics, Mar 1998, Vol. 284, No. 3, pgs. 847-857
		Thwin, Muang-Muang et al., "Functional site of endogenous phospholipase A <sub>2</sub> inhibitor from python serum," European Journal of Biochemistry/Febs. Jan 2002, vol. 269, 719-727
		Furue, Shingo, MS. et al., "Therapeutic time-window of a group IIA phospholipase A <sub>2</sub> inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection," Critical Care Medicine, April 2001, vol. 29, no. 4, pgs. 719-727
		Niessen, Hans W.M. et al., "Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?" Cardiovascular Research, 15 Oct. 2003, vol. 60, no. 1, 4 September 2003, pgs. 68-77
		Graff, Jeremy R. et al., "Expression of Group IIA Secretory Phospholipase A2 Increases with Prostate Tumor Grade," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Dec. 2001, vol. 7, no. 12, December 2001, pgs. 3857-3861
		Bidgood, Matthew J. et al., "Type IIA Secretory Phospholipase A <sub>2</sub> Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes" Journal of Immunology, September 1, 2000, vol. 165, no. 5, pgs. 2790-2797
		Menschikowski, M. et al. "Expression of Secretory Group IIA Phospholipase A <sub>2</sub> in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues," Arterioscler Thromb Vasc. Biol, pgs. 751-762 June 16, 1999

Examiner Signature

Date Considered

<sup>†</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.